BERLIN — German pharmaceutical company CureVac says it has begun submitting data on its coronavirus vaccine to the EU regulator with the aim of speeding up the approval process.

The Amsterdam-based European Medicines Agency confirmed Friday that it has begun a review of the vaccine and that early laboratory and clinical studies indicate it triggers an immune response against the virus.

Tuebingen-based CureVac is still conducting further trials of the vaccine, but the rolling review process means EMA will be able to reduce the amount of time needed to decide whether to approve it once all the necessary data has been submitted. The same approach led to the approval of vaccines made by Pfizer/BioNTech, Moderna and AstraZeneca.

CureVac’s vaccine uses the same mRNA technology as those made by Pfizer and Moderna.

The company said the vaccine is currently being trialed in healthy adults in Europe and Latin America.